An Envisia positive result may serve as a biomarker for FVC by identifying the genomic signature of UIP in patients without definite UIP on CT. Results for the study showed that patients with an Envisia positive result show a greater decline in FVC over time compared to Envisia negative patients.
These findings show that an Envisia positive result may help identify patients in whom two-drug immunosuppressive therapy is harmful. These results further support the utility of Envisia, highlighting the potential of an Envisia positive result to inform both diagnosis and treatment decisions, identifying patients in whom antifibrotic therapy may be preferred.
ATS Webinar
Presented by: Fayez Kheir, MD & Mary Beth Scholand, MD.
In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.
Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.
PIPELINE
Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.
Transform uncertainty into confidence
Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.